FDA building disease models
Executive Summary
FDA and the drug development software firm Pharsight have entered into a cooperative research and development agreement to license software modules for "the analysis, visualization, storage, reporting and review of pharmacokinectic/pharmacodynamic data" and development of a "repository for the data needed for modeling and simulation" as well as support for the Clinical Data Interchange Standards Consortium, the company says. FDA says the agreement will help the agency apply model-based drug development tools to regulatory decisions and build disease, placebo, dropout and drug efficacy/safety models...
You may also be interested in...
‘Clear’ Is In The Eye Of The Beholder, New York, CRN Argue In Age-Restricted Sales Litigation
CRN’s request for clarification, as it continues litigating complaint in US District Court for Southern New York, highlights what it contends is vague and overly general language in the legislation passed in October with a 22 April effective date.
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.